Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for immunotherapeutic strategies. Modulation of the tumor micr...

Full description

Bibliographic Details
Main Authors: Kerstin Kapp, Barbara Volz, Detlef Oswald, Burghardt Wittig, Matthias Baumann, Manuel Schmidt
Format: Article
Language:English
Published: Taylor & Francis Group 2019-12-01
Series:OncoImmunology
Subjects:
mgn1703
cancer immunotherapy
tumor microenvironment
immune checkpoint inhibitors
anti-tumor memory
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1659096

Internet

http://dx.doi.org/10.1080/2162402X.2019.1659096

Similar Items